Latest On OptimizeRx Corporation (OPRX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 09:05 EST | News | OptimizeRx Corporation (OPRX) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-10 19:14 EST | News | OptimizeRx Non-GAAP EPS of -$0.09 misses by $0.01, revenue of $13M beats by $0.64M | N/A | |
| 2023-05-10 05:58 EST | News | OptimizeRx Q1 2023 Earnings Preview | N/A | |
| 2023-04-04 01:29 EST | News | OptimizeRx Has A Good Growth Path Ahead | N/A | |
| 2023-03-14 08:26 EST | News | OptimizeRx launches $15M stock buyback plan | N/A | |
| 2023-03-09 20:46 EST | News | OptimizeRx bags contract with Hub services company for better patient access | N/A | |
| 2023-03-09 05:10 EST | News | OptimizeRx Q4 results mixed, co sees FY 2023 Y/Y revenue growth below consensus | N/A | |
| 2023-03-09 05:10 EST | News | OptimizeRx Q4 top line miss, lackluster 2023 revenue guidance drives shares down 19% | N/A | |
| 2023-03-09 05:10 EST | News | OptimizeRx Corporation (OPRX) Q4 2022 Earnings Call Transcript | N/A | |
| 2022-11-09 10:21 EST | News | OptimizeRx Corporation (OPRX) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-08 17:11 EST | News | OptimizeRx Non-GAAP EPS of $0.07 beats by $0.03, revenue of $15.1M beats by $0.08M | N/A | |
| 2022-11-07 23:01 EST | News | OptimizeRx Q3 2022 Earnings Preview | N/A | |
| 2022-10-25 15:02 EST | News | OptimizeRx: A Digital Health Marketing Firm That Has Fallen On Hard Times | N/A | |
| 2022-10-12 08:35 EST | News | OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio | N/A | |
| 2022-08-10 21:45 EST | News | OptimizeRx stock sinks 26% on Q2 miss, while FY22 outlook cut on life sciences sector woes | N/A | |
| 2022-08-10 04:11 EST | News | OptimizeRx Q2 Non-GAAP EPS, revenue misses, FY22 guidance below consensus | N/A | |
| 2022-08-10 04:11 EST | News | OptimizeRx Corporation (OPRX) CEO William Febbo on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-09 06:21 EST | News | OptimizeRx Q2 2022 Earnings Preview | N/A | |
| 2022-07-26 19:41 EST | News | OptimizeRx extends reach with Cooler Screens Partnership | N/A | |
| 2022-06-27 13:25 EST | News | OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability | N/A | |
| 2022-06-26 19:34 EST | News | OptimizeRx (OPRX) Investor Presentation - Slideshow | N/A | |
| 2022-05-17 14:46 EST | News | OptimizeRx authorizes $20M share repurchase program | N/A | |
| 2022-05-05 07:30 EST | News | OptimizeRx Non-GAAP EPS of -$0.01 in-line, revenue of $13.73M beats by $0.18M | N/A | |
| 2022-05-05 07:29 EST | News | OptimizeRx Corporation (OPRX) CEO William Febbo on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-03 18:55 EST | News | OptimizeRx Q1 2022 Earnings Preview | N/A | |
| 2022-03-16 08:15 EST | News | OptimizeRx to acquire specialty drug prescription platform Evincemed | N/A | |
| 2022-02-25 12:37 EST | News | OptimizeRx's (OPRX) CEO William Febbo on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-24 17:00 EST | News | OptimizeRx Non-GAAP EPS of $0.22 beats by $0.18, revenue of $20.3M beats by $5.5M | N/A | |
| 2022-02-24 00:04 EST | News | OptimizeRx Q4 2022 Earnings Preview | N/A | |
| 2022-02-16 04:57 EST | News | OptimizeRx announces preliminary Q4 results | N/A | |
| 2021-11-10 13:38 EST | News | OptimizeRx EPS misses by $0.04, beats on revenue | N/A | |
| 2021-11-10 13:38 EST | News | OptimizeRx's (OPRX) CEO William Febbo on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-09 14:32 EST | News | OptimizeRx Q3 2021 Earnings Preview | N/A | |
| 2021-09-30 20:19 EST | News | OptimizeRx names Edward Stelmakh as CFO and COO | N/A | |
| 2021-09-29 20:59 EST | News | OptimizeRx jumps 11% on addition to SmallCap 600 index | N/A | |
| 2021-08-05 10:49 EST | News | OptimizeRx Corporation (OPRX) CEO William Febbo on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-21 18:39 EST | News | OptimizeRx inks collaboration agreement to drive new patient affordability initiative | N/A | |
| 2021-04-20 09:36 EST | News | OptimizeRx Stock Is Just Getting Started | N/A | |
| 2021-03-17 05:40 EST | News | OptimizeRx nabs 19 new enterprise-level engagements in Q1 leading to recurring revenue | N/A | |
| 2021-03-02 12:13 EST | Analyst Rating | The Analyst Target Price has increased from $65.33 to $75.33. | Buy | |
| 2021-02-26 12:08 EST | Analyst Rating | The Analyst Target Price has increased from $61.33 to $65.33. | Buy | |
| 2021-02-26 04:22 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-25 14:02 EST | Earnings Estimate | An EPS average of $0.07 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-02-25 14:02 EST | Earnings Estimate | An EPS average of $0.78 is estimated for the 2022 year. | Buy | |
| 2021-02-25 07:12 EST | News | OptimizeRx EPS beats by $0.01, beats on revenue | N/A | |
| 2021-02-25 07:10 EST | News | OptimizeRx Corporation (OPRX) CEO William Febbo on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-02-10 16:32 EST | News | OptimizeRx announces proposed public offering | N/A | |
| 2021-02-10 16:31 EST | News | OptimizeRx priced its stock offering | N/A | |
| 2021-01-26 12:20 EST | Analyst Rating | The Analyst Target Price has increased from $53.33 to $61.33. | Buy | |
| 2021-01-25 20:45 EST | News | OptimizeRx trades high on positive Q4 guidance | N/A | |
About OptimizeRx Corporation (OPRX):
OptimizeRx Corporation operates as a digital health company that provides communications solutions for life science companies, physicians, and patients. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, therapeutic support messages, and unbranded messages. The company also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, it operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, the company offers patient programs with treatment and affordability information, lifestyle and condition trackers, Internet device connectivity, forms, and surveys. OptimizeRx Corporation is headquartered in Rochester, Michigan.
General
- Name OptimizeRx Corporation
- Symbol OPRX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryHealth Information Services
- Full Time Employees 71
- Last Split Factor1:3
- Last Split Date2018-05-14
- Fiscal Year EndDecember
- IPO Date1996-10-22
- Gic SectorHealth Care
- Gic GroupHealth Care Equipment & Services
- Gic IndustryHealth Care Technology
- Gic SubIndustryHealth Care Technology
- Web URLhttp://www.optimizerx.com
View More
Valuation
- Forward PE 96.15
- Price/Sales (Trailing 12 Mt.) 15.5
- Price/Book (Most Recent Quarter) 15.23
- Enterprise Value Revenue 17.34
- Enterprise Value EBITDA 467.33
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $0.44
- Next Year EPS Estimate $0.81
- Next Quarter EPS Estimate $0.03
- Profit Margin -5%
- Operating Margin -3%
- Return on Assets -1%
- Return on Equity -5%
- Revenue 43.31 million
- Earnings Per Share $0.04
- Revenue Per Share $2.92
- Gross Profit 24.11 million
- Quarterly Earnings Growth 122.6%
View More
Highlights
- Market Capitalization 839.66 million
- EBITDA 646895
- PE Ratio -8.5
- PEG Ratio 1.93
- Analyst Target Price $75.33
- Book Value Per Share $3.28
View More
Share Statistics
- Shares Outstanding 16.81 million
- Shares Float 14.36 million
- % Held by Insiders 1791%
- % Held by Institutions 65.76%
- Shares Short 871014
- Shares Short Prior Month 930303
- Short Ratio 2.63
- Short % of Float 5%
- Short % of Shares Outstanding 5%
View More
Technicals
- Beta 0.66
- 52 Week High $63.98
- 52 Week Low $6.51
- 50 Day Moving Average 51.77
- 200 Day Moving Average 32.49
View More
Dividends
- Dividend Date 2018-05-14
- ExDividend Date N/A
- Dividend Yield 0%
View More
OptimizeRx Corporation (OPRX) Dividend Calendar:
OPRX's last dividend payment was made to shareholders on May 14, 2018.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
OptimizeRx Corporation (OPRX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-24 | $N/A | $0.16 | $0.16 | 3.23% |
| 2020-09-30 | 2020-11-09 | $N/A | $0.06 | $0.04 | 55.75% |
| 2020-06-30 | 2020-08-05 | $N/A | $0.02 | -$0.03 | 166.67% |
| 2020-03-31 | 2020-05-04 | $N/A | -$0.06 | -$0.03 | -100% |
| 2019-12-31 | 2020-02-27 | $7.38 million | -$0.03 | $0.01 | -700% |
| 2019-09-30 | 2019-11-05 | $5 million | -$0.05 | $0.08 | -164.52% |
| 2019-06-30 | 2019-08-07 | $7.01 million | $0.09 | $0.08 | 16.13% |
| 2019-03-31 | 2019-05-08 | $5.21 million | $0.06 | $0.02 | 166.67% |
| 2018-12-31 | 2019-02-26 | $6.58 million | $0.06 | $0.07 | -18.14% |
| 2018-09-30 | 2018-11-05 | $5.42 million | $0.07 | $0.06 | 23% |
| 2018-06-30 | 2018-08-07 | $5.1 million | $0.07 | $0.03 | 166.8% |
| 2018-03-31 | 2018-05-02 | $4.11 million | $0.03 | -$0.03 | 205% |
| 2017-12-31 | 2018-02-27 | $4.01 million | $0.02 | -$0.03 | 157% |
| 2017-09-30 | 2017-11-02 | $3.1 million | -$0.04 | -$0.03 | -43% |
| 2017-06-30 | 2017-08-01 | $2.87 million | -$0.03 | ||
| 2017-03-31 | 2017-05-03 | $2.15 million | -$0.09 | ||
| 2016-12-31 | 2017-03-08 | $2.29 million | -$0.04 | ||
| 2016-09-30 | 2016-11-07 | $1.79 million | -$0.02 | ||
| 2016-06-30 | 2016-08-08 | $1.91 million | -$0.03 | -$0.03 | 0% |
| 2016-03-31 | 2016-05-09 | $1.76 million | -$0.01 | -$0.03 | 66.67% |
| 2015-12-31 | 2016-03-15 | $2.02 million | -$0.01 | ||
| 2015-09-30 | 2015-11-12 | $2.01 million | $0.01 | ||
| 2015-06-30 | 2015-08-11 | $1.71 million | -$0.01 | ||
| 2015-03-31 | 2015-05-14 | $1.49 million | -$0.01 | ||
| 2014-12-31 | 2015-03-31 | $1.97 million | $0.00 | $0.01 | -100% |
| 2014-09-30 | 2014-11-13 | $1.82 million | -$0.02 | ||
| 2014-06-30 | 2014-08-14 | $1.43 million | -$0.01 | $0.03 | -122.67% |
| 2014-03-31 | 2014-05-28 | $1.29 million | -$0.12 | ||
| 2013-12-31 | 2013-12-31 | $1.53 million | -$0.01 | ||
| 2013-09-30 | 2013-09-30 | $1.37 million | $0.00 | ||
| 2013-06-30 | 2013-06-30 | $1.1 million | $0.03 | ||
| 2013-03-31 | 2013-03-31 | $669000 | -$0.02 | ||
| 2012-12-31 | 2012-12-31 | $0.07 | |||
| 2012-09-30 | 2012-09-30 | -$0.02 | |||
| 2012-06-30 | 2012-06-30 | -$0.02 | |||
| 2012-03-31 | 2012-03-31 | -$0.06 | |||
| 2011-12-31 | 2011-12-31 | -$0.11 | |||
| 2011-09-30 | 2011-09-30 | $191593 | -$0.21 | ||
| 2011-06-30 | 2011-06-30 | $200174 | -$0.09 | ||
| 2011-03-31 | 2011-03-31 | -$0.05 | |||
| 2010-12-31 | 2010-12-31 | -$0.08 | |||
| 2010-09-30 | 2010-09-30 | -$0.11 | |||
| 2010-06-30 | 2010-06-30 | -$0.20 | |||
| 2010-03-31 | 2010-03-31 | -$0.06 | |||
| 2009-12-31 | 2009-12-31 | -$0.54 | |||
| 2009-09-30 | 2009-09-30 | -$0.12 | |||
| 2009-06-30 | 2009-06-30 | -$0.08 | |||
| 2009-03-31 | 2009-03-31 | -$0.33 | |||
| 2008-12-31 | 2008-12-31 | -$0.84 | |||
| 2008-09-30 | 2008-09-30 | -$0.04 | |||
| 2008-06-30 | 2008-06-30 | -$0.14 | |||
| 2008-03-31 | 2008-03-31 | -$158.21 |
OptimizeRx Corporation (OPRX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | N/A |
| Income Before Tax | N/A | N/A | N/A | -2.2 million | -2.89 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 5.76 million |
| Gross Profit | N/A | N/A | N/A | N/A | 4.47 million |
| Ebit | N/A | N/A | N/A | N/A | -2.32 million |
| Operating Income | N/A | N/A | N/A | -2.26 million | -2.32 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | -897960 |
| Total Revenue | N/A | N/A | N/A | N/A | 7.38 million |
| Cost of Revenue | N/A | N/A | N/A | N/A | 2.91 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -567278 |
| Net Income From Continuing Operations | N/A | N/A | N/A | -2.2 million | -1.99 million |
| Net Income Applicable to Common Shares | 1.36 million | -282894 | -1.08 million | -2.2 million | -1.99 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | -203655 | 105896 | -33471 | -766603 | 530192 |
| Total Cash Flow from Investing Activities | -20256 | -9061 | -15937 | -9.52 million | -13718 |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | 112152 | 113279 | 206324 |
| Change to Operating Activities | 1.52 million | 1.51 million | -1.23 million | 310250 | -824717 |
| Change in Cash | N/A | N/A | N/A | -10.91 million | -776453 |
| Total Cash from Operating Activities | -106598 | 127643 | -3.74 million | -1.5 million | -969059 |
| Depreciation | N/A | N/A | N/A | 536859 | 320055 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | 151719 | 266109 |
| Other Cash Flow from Financing Activities | -3 million | -1.39 million | N/A | 301711 | N/A |
| Change to Net Income | 906827 | 850671 | 854512 | 252618 | 310244 |
| Capital Expenditures | N/A | N/A | N/A | 26260 | 13718 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | 12.61 million | 11.78 million |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 44.86 million |
| Other Current Liabilities | 6.87 million | 5.71 million | N/A | N/A | 3.7 million |
| Total Assets | N/A | N/A | N/A | 56.24 million | 56.64 million |
| Common Stock | 15223 | 15072 | 14753 | 14647 | 14601 |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -35.63 million | -36.99 million | -36.71 million | -35.63 million | -33.42 million |
| Other Liabilities | N/A | N/A | N/A | 2.72 million | 5.22 million |
| Other Assets | 12859 | 16013 | 35943 | 16013 | 80727 |
| Cash | N/A | N/A | N/A | 15.21 million | 18.85 million |
| Total Current Liabilities | 10.03 million | 8.11 million | N/A | 9.47 million | 6.11 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 594828 | 626715 | 660056 | 701967 | 735877 |
| Total Current Assets | 32.86 million | 27.23 million | N/A | N/A | 27.14 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 23.11 million | 19.41 million | 15.76 million | 15.41 million | 16.18 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 618250 | 480502 | N/A | N/A | 492995 |
OptimizeRx Corporation (OPRX) Chart:
OptimizeRx Corporation (OPRX) News:
Below you will find a list of latest news for OptimizeRx Corporation (OPRX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
OptimizeRx Corporation (OPRX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-01-17 | 2.5 | 0 | CALL | 0 | 0 | 119.9 | TRUE | 0 | 0 |
| 2025-01-17 | 5 | 0 | CALL | 0 | 0 | 83.14 | TRUE | 0 | 0 |
| 2025-01-17 | 7.5 | 2.27 | CALL | 0 | 3 | 95.63 | FALSE | 0 | 0 |
| 2025-01-17 | 10 | 0.3 | CALL | 0 | 255 | 61.78 | FALSE | 0 | 0 |
| 2025-01-17 | 12.5 | 5.18 | CALL | 0 | 15 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 15 | 0.6 | CALL | 0 | 272 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 17.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 20 | 1.95 | CALL | 0 | 7 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 22.5 | 0.38 | CALL | 0 | 7 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 25 | 0.25 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 30 | 0.55 | CALL | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 35 | 0.1 | CALL | 0 | 24 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 7.5 | 0.45 | PUT | 0 | 1 | 0 | TRUE | 0 | 0 |
| 2025-01-17 | 10 | 2.35 | PUT | 0 | 215 | 60.06 | TRUE | 0 | 0 |
| 2025-01-17 | 12.5 | 2.25 | PUT | 0 | 10 | 156.39 | TRUE | 0 | 0 |
| 2025-01-17 | 15 | 4.2 | PUT | 0 | 1 | 178.77 | TRUE | 0 | 0 |
| 2025-01-17 | 17.5 | 0 | PUT | 0 | 0 | 190.34 | TRUE | 0 | 0 |
| 2025-01-17 | 20 | 0 | PUT | 0 | 0 | 153.64 | TRUE | 0 | 0 |
| 2025-01-17 | 22.5 | 15.1 | PUT | 0 | 0 | 223.86 | TRUE | 0 | 0 |
| 2025-01-17 | 25 | 9.23 | PUT | 0 | 0 | 180.1 | TRUE | 0 | 0 |
| 2025-01-17 | 30 | 0 | PUT | 0 | 0 | 197.96 | TRUE | 0 | 0 |
| 2025-01-17 | 35 | 0 | PUT | 0 | 0 | 151.8 | TRUE | 0 | 0 |
| 2025-03-21 | 2.5 | 0 | CALL | 0 | 0 | 86.7 | TRUE | 0 | 0 |
| 2025-03-21 | 5 | 3 | CALL | 0 | 7 | 86.03 | TRUE | 0 | 0 |
| 2025-03-21 | 7.5 | 1.3 | CALL | 0 | 38 | 59.78 | FALSE | 0 | 0 |
| 2025-03-21 | 10 | 1.75 | CALL | 0 | 0 | 73.73 | FALSE | 0 | 0 |
| 2025-03-21 | 12.5 | 0 | CALL | 0 | 0 | 57.27 | FALSE | 0 | 0 |
| 2025-03-21 | 15 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 17.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 20 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 7.5 | 0 | PUT | 0 | 0 | 73.28 | TRUE | 0 | 0 |
| 2025-03-21 | 10 | 0 | PUT | 0 | 0 | 60.98 | TRUE | 0 | 0 |
| 2025-03-21 | 12.5 | 0 | PUT | 0 | 0 | 56.9 | TRUE | 0 | 0 |
| 2025-03-21 | 15 | 0 | PUT | 0 | 0 | 65.23 | TRUE | 0 | 0 |
| 2025-03-21 | 17.5 | 0 | PUT | 0 | 0 | 118.47 | TRUE | 0 | 0 |
| 2025-03-21 | 20 | 0 | PUT | 0 | 0 | 87.42 | TRUE | 0 | 0 |
Latest OPRX Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 1 | $25.31 |
| Jun 13, 2022 7:59 PM EST | 85 | $25.28 |
| Jun 13, 2022 7:59 PM EST | 30 | $25.32 |
| Jun 13, 2022 7:59 PM EST | 23 | $25.32 |
| Jun 13, 2022 8:45 PM EST | 2 | $25.99 |
OptimizeRx Corporation (OPRX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020016585/0001213900-20-016585-index.htm |
| 2020-02-27 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1448431/000103347520000005/0001033475-20-000005-index.htm |
| 2020-02-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020004998/0001213900-20-004998-index.htm |
| 2020-03-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020005137/0001213900-20-005137-index.htm |
| 2020-03-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020005258/0001213900-20-005258-index.htm |
| 2020-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020005495/0001213900-20-005495-index.htm |
| 2020-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020005596/0001213900-20-005596-index.htm |
| 2020-03-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020005688/0001213900-20-005688-index.htm |
| 2020-03-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020005874/0001213900-20-005874-index.htm |
| 2020-03-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020005969/0001213900-20-005969-index.htm |
| 2020-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020006161/0001213900-20-006161-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020006356/0001213900-20-006356-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020006358/0001213900-20-006358-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020006360/0001213900-20-006360-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020006361/0001213900-20-006361-index.htm |
| 2020-03-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020006460/0001213900-20-006460-index.htm |
| 2020-03-16 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020006534/0001213900-20-006534-index.htm |
| 2020-03-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020006751/0001213900-20-006751-index.htm |
| 2020-03-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020007331/0001213900-20-007331-index.htm |
| 2020-03-26 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1448431/000121390020007491/0001213900-20-007491-index.htm |
| 2020-03-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020008137/0001213900-20-008137-index.htm |
| 2020-03-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020008138/0001213900-20-008138-index.htm |
| 2020-03-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020008139/0001213900-20-008139-index.htm |
| 2020-03-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020008140/0001213900-20-008140-index.htm |
| 2020-04-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020008316/0001213900-20-008316-index.htm |
| 2020-04-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020008456/0001213900-20-008456-index.htm |
| 2020-04-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020008624/0001213900-20-008624-index.htm |
| 2020-04-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020008867/0001213900-20-008867-index.htm |
| 2020-04-10 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1448431/000121390020008955/0001213900-20-008955-index.htm |
| 2020-04-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020009315/0001213900-20-009315-index.htm |
| 2020-04-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020009488/0001213900-20-009488-index.htm |
| 2020-04-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020009800/0001213900-20-009800-index.htm |
| 2020-05-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020010957/0001213900-20-010957-index.htm |
| 2020-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020011117/0001213900-20-011117-index.htm |
| 2020-05-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1448431/000121390020011158/0001213900-20-011158-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020011286/0001213900-20-011286-index.htm |
| 2020-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020011394/0001213900-20-011394-index.htm |
| 2020-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020012040/0001213900-20-012040-index.htm |
| 2020-05-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020012894/0001213900-20-012894-index.htm |
| 2020-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020013773/0001213900-20-013773-index.htm |
| 2020-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020014108/0001213900-20-014108-index.htm |
| 2020-06-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020014568/0001213900-20-014568-index.htm |
| 2020-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020015899/0001213900-20-015899-index.htm |
| 2020-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020015991/0001213900-20-015991-index.htm |
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020016166/0001213900-20-016166-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020016579/0001213900-20-016579-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020016581/0001213900-20-016581-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020016582/0001213900-20-016582-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020016584/0001213900-20-016584-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020016585/0001213900-20-016585-index.htm |
| 2020-07-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020016870/0001213900-20-016870-index.htm |
| 2020-07-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020017235/0001213900-20-017235-index.htm |
| 2020-07-10 | 144 | Report of proposed sale of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020017236/0001213900-20-017236-index.htm |
| 2020-07-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020017818/0001213900-20-017818-index.htm |
| 2020-07-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020018238/0001213900-20-018238-index.htm |
| 2020-07-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020018352/0001213900-20-018352-index.htm |
| 2020-07-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020018775/0001213900-20-018775-index.htm |
| 2020-08-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1448431/000121390020020375/0001213900-20-020375-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020020566/0001213900-20-020566-index.htm |
| 2020-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020020802/0001213900-20-020802-index.htm |
| 2020-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020020933/0001213900-20-020933-index.htm |
| 2020-08-11 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020021320/0001213900-20-021320-index.htm |
| 2020-08-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020021359/0001213900-20-021359-index.htm |
| 2020-08-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020022333/0001213900-20-022333-index.htm |
| 2020-08-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020023057/0001213900-20-023057-index.htm |
| 2020-08-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020023388/0001213900-20-023388-index.htm |
| 2020-09-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020025434/0001213900-20-025434-index.htm |
| 2020-09-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020025765/0001213900-20-025765-index.htm |
| 2020-09-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020026656/0001213900-20-026656-index.htm |
| 2020-09-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020027474/0001213900-20-027474-index.htm |
| 2020-10-01 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1448431/000121390020029583/0001213900-20-029583-index.htm |
| 2020-10-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020031051/0001213900-20-031051-index.htm |
| 2020-10-16 | 144 | Report of proposed sale of securities | https://www.sec.gov/Archives/edgar/data/1448431/000121390020031790/0001213900-20-031790-index.htm |
| 2020-10-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1448431/000121390020033259/0001213900-20-033259-index.htm |
OptimizeRx Corporation (OPRX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of OptimizeRx Corporation (OPRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1791%Institutional Ownership: 6576%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-08-06 | DOUGLAS P BAKER | CHIEF FINANCIAL OFFICER | Sell | 10,000.00 | 17.01 | 170,100.00 | 100,671.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020020933/0001213900-20-020933-index.htm |
| 2020-08-13 | DOUGLAS P BAKER | CHIEF FINANCIAL OFFICER | Sell | 10,000.00 | 18.00 | 180,000.00 | 100,671.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020022333/0001213900-20-022333-index.htm |
| 2020-08-07 | DOUGLAS P BAKER | CHIEF FINANCIAL OFFICER | Buy | 10,000.00 | 2.46 | 24,600.00 | 110,671.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020020933/0001213900-20-020933-index.htm |
| 2020-08-14 | DOUGLAS P BAKER | CHIEF FINANCIAL OFFICER | Buy | 10,000.00 | 2.46 | 24,600.00 | 110,671.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020022333/0001213900-20-022333-index.htm |
| 2020-08-07 | GREGORY D WASSON | Director | Buy | 15,000.00 | 17.49 | 262,350.00 | 15,000.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020021359/0001213900-20-021359-index.htm |
| 2020-03-04 | WILLIAM J FEBBO | CHIEF EXECUTIVE OFFICER | Buy | 30,000.00 | 3.21 | 96,300.00 | 163,267.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020005495/0001213900-20-005495-index.htm |
| 2020-03-30 | Patrick D Spangler | Director | Buy | 2,784.00 | 17,467.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020008140/0001213900-20-008140-index.htm | ||
| 2020-06-30 | Patrick D Spangler | Director | Buy | 1,937.00 | 19,404.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020016584/0001213900-20-016584-index.htm | ||
| 2020-06-24 | WILLIAM J FEBBO | CHIEF EXECUTIVE OFFICER | Buy | 45,261.00 | 3.21 | 145,287.81 | 208,528.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020015899/0001213900-20-015899-index.htm |
| 2020-06-30 | WILLIAM J FEBBO | CHIEF EXECUTIVE OFFICER | Buy | 21,187.00 | 229,719.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020016579/0001213900-20-016579-index.htm | ||
| 2020-03-30 | Ellen O'Connor Vos | Director | Buy | 2,784.00 | 27,022.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020008138/0001213900-20-008138-index.htm | ||
| 2020-03-30 | James Paul Lang | Director | Buy | 2,784.00 | 27,792.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020008137/0001213900-20-008137-index.htm | ||
| 2020-03-31 | Ellen O'Connor Vos | Director | Buy | 1,000.00 | 8.75 | 8,750.00 | 28,022.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020008316/0001213900-20-008316-index.htm |
| 2020-06-30 | James Paul Lang | Director | Buy | 1,937.00 | 29,729.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020016582/0001213900-20-016582-index.htm | ||
| 2020-06-30 | Ellen O'Connor Vos | Director | Buy | 1,937.00 | 29,959.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020016585/0001213900-20-016585-index.htm | ||
| 2020-03-30 | GUS D HALAS | Director | Buy | 2,784.00 | 59,960.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020008139/0001213900-20-008139-index.htm | ||
| 2020-06-30 | GUS D HALAS | Director | Buy | 1,937.00 | 61,897.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020016581/0001213900-20-016581-index.htm | ||
| 2020-09-02 | DOUGLAS P BAKER | CHIEF FINANCIAL OFFICER | Sell | 10,000.00 | 20.00 | 200,000.00 | 80,705.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020025434/0001213900-20-025434-index.htm |
| 2020-07-16 | DOUGLAS P BAKER | CHIEF FINANCIAL OFFICER | Sell | 6,667.00 | 15.00 | 100,005.00 | 82,671.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020017818/0001213900-20-017818-index.htm |
| 2020-06-03 | DOUGLAS P BAKER | CHIEF FINANCIAL OFFICER | Buy | 17,421.00 | 3.15 | 54,876.15 | 89,338.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020014108/0001213900-20-014108-index.htm |
| 2020-07-17 | DOUGLAS P BAKER | CHIEF FINANCIAL OFFICER | Buy | 8,000.00 | 2.46 | 19,680.00 | 90,671.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020017818/0001213900-20-017818-index.htm |
| 2020-09-02 | DOUGLAS P BAKER | CHIEF FINANCIAL OFFICER | Buy | 10,000.00 | 2.46 | 24,600.00 | 90,705.00 | https://www.sec.gov/Archives/edgar/data/1448431/000121390020025434/0001213900-20-025434-index.htm |